Information Provided By:
Fly News Breaks for January 22, 2016
DEPO
Jan 22, 2016 | 09:13 EDT
Roth Capital named Depomed as its top specialty pharma pick for 2016. The firm says that, based on recent data, revenue from the company's Nucynta ER drug appears to be increasing about 20% year-over-year. The firm thinks this revenue growth could enable the company's EPS to beat expectations, causing its valuation to expand. Roth keeps a $26 price target and Buy rating on the shares.
News For DEPO From the Last 2 Days
There are no results for your query DEPO